Please assess the completion status of the following clinical trial:

Trial Title: Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of type 2 diabetes mellitus prior to informed consent~* Male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are:~  * drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or,~ * pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.)~* Glycosylated haemoglobin (HbA1c) at Visit 1 (screening)~  * for patients without antidiabetic therapy : HbA1c \>=7.0 to =\<10.0%~ * for patients with one oral antidiabetic drug : HbA1c \>=7.0 to =\<9.5%~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \>240 mg/dL (\>13.3 mmol/L)~* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (MDRD) formula)~* Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent~* Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin low dose (Type: EXPERIMENTAL): Empagliflozin low dose tablet once daily
- Empagliflozin high dose (Type: EXPERIMENTAL): Empagliflozin high dose tablet once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).